Kinase Inhibitors Produced Selective Changes in Established THC Tolerance
A behavioral experiment found that kinase inhibitors differed in their ability to reverse established THC tolerance. PKA inhibition affected all measured behaviors, while other inhibitor classes produced selective or null results.
Reversal was the question being tested
The study examined signaling pathways involved in expression of tolerance after repeated THC administration. This differs from asking whether an intervention prevents tolerance during its development. The investigators compared inhibitors directed at several kinase pathways across multiple THC-related behavioral measures.
The positive and null findings differed
PKA inhibition reversed tolerance across the measures described, but the effective inhibitor doses and time courses varied by behavior. Src tyrosine kinase inhibition reversed tolerance only to THC-related hypoactivity. The tested PKG- and PKC-directed inhibitors did not reverse tolerance on any behavioral measure. Those null results are part of the study's central pattern.
Behavioral effects do not measure enzyme activity directly
An inhibitor changing a tolerated behavior supports involvement of a signaling pathway under those conditions. It does not, by itself, show that chronic THC increased the pathway's overall activity throughout the brain. Direct enzyme assays and behavioral intervention experiments address related but different questions.
The evidence supports selective pathway involvement, rather than a practical tolerance-reset regimen. The abstract does not establish human efficacy, consumer dosing or safety for these experimental interventions. Any interpretation should preserve the measured behavior and the timing of inhibition rather than generalizing the PKA finding to every consequence of cannabis use.
Related: interpreting cannabis tolerance claims.
Research cited
Bass CE; Welch SP; Martin BR. Reversal of delta 9-tetrahydrocannabinol-induced tolerance by specific kinase inhibitors. European journal of pharmacology (2004). doi:10.1016/j.ejphar.2004.06.009. Findings discussed from the study abstract.
